Therapeutic effects of chitooligosaccharide-epigallocatechin gallate conjugate on NAFLD: impact on gut-liver axis, lipid metabolism, and inflammation in rats fed a high-fat diet - PubMed
4 hours ago
- #NAFLD
- #Lipid Metabolism
- #Gut-Liver Axis
- The study explores the therapeutic effects of a conjugate made from chitooligosaccharide (COS) and epigallocatechin gallate (EGCG) on non-alcoholic fatty liver disease (NAFLD) in rats fed a high-fat diet.
- Treatment with COS-EGCG conjugate reduced liver fat accumulation and injury by downregulating lipid synthesis genes (CD36, FASN, SREBP-1c) and upregulating lipid metabolism genes (PPARα, CPT1A, MTTP).
- The conjugate positively influenced the gut-liver axis by modulating gut microbiota, lowering serum lipopolysaccharide (LPS) levels, and restoring intestinal tight junction proteins (ZO-1 and occludin) to improve gut barrier function.
- It also inhibited liver inflammation by suppressing the LPS-induced TLR4/NF-κB signaling pathway, highlighting its anti-inflammatory effects.
- Results suggest COS-EGCG conjugate as a potential dietary therapy for NAFLD, addressing lipid metabolism, gut dysbiosis, and inflammation through multi-target mechanisms.